The Library
Baroreflex activation therapy with the Barostim ™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials
Tools
Tools
Tools
Coats, Andrew J. S., Abraham, William T., Zile, Michael R., Lindenfeld, Joann A., Weaver, Fred A., Fudim, Marat, Bauersachs, Johann, Duval, Sue, Galle, Elizabeth and Zannad, Faiez (2022) Baroreflex activation therapy with the Barostim ™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials. European Journal of Heart Failure, 24 (9). pp. 1665-1673. doi:10.1002/ejhf.2573 ISSN 1879-0844.
|
PDF
WRAP-Baroreflex-activation-therapy-patients-heart-failure-ejection-fraction-trials-2022.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons: Attribution-Noncommercial 4.0. Download (588Kb) | Preview |
Official URL: https://doi.org/10.1002/ejhf.2573
Abstract
Aims: Heart failure with reduced ejection fraction (HFrEF) remains associated with high morbidity and mortality, poor quality of life (QoL) and significant exercise limitation. Sympatho‐vagal imbalance has been shown to predict adverse prognosis and symptoms in HFrEF, yet it has not been specifically targeted by any guideline‐recommended device therapy to date. Barostim™, which directly addresses this imbalance, is the first Food and Drug Administration approved neuromodulation technology for HFrEF. We aimed to analyse all randomized trial evidence to evaluate the effect of baroreflex activation therapy (BAT) on heart failure symptoms, QoL and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) in HFrEF. Methods and results: An individual patient data (IPD) meta‐analysis was performed on all eligible trials that randomized HFrEF patients to BAT + guideline‐directed medical therapy (GDMT) or GDMT alone (open label). Endpoints included 6‐month changes in 6‐min hall walk (6MHW) distance, Minnesota Living With Heart Failure (MLWHF) QoL score, NT‐proBNP, and New York Heart Association (NYHA) class in all patients and three subgroups. A total of 554 randomized patients were included. In all patients, BAT provided significant improvement in 6MHW distance of 49 m (95% confidence interval [CI] 33, 64), MLWHF QoL of −13 points (95% CI −17, −10), and 3.4 higher odds of improving at least one NYHA class (95% CI 2.3, 4.9) when comparing from baseline to 6 months. These improvements were similar, or better, in patients who had baseline NT‐proBNP <1600 pg/ml, regardless of the cardiac resynchronization therapy indication status. Conclusion: An IPD meta‐analysis suggests that BAT improves exercise capacity, NYHA class, and QoL in HFrEF patients receiving GDMT. These clinically meaningful improvements were consistent across the range of patients studies. BAT was also associated with an improvement in NT‐proBNP in subjects with a lower baseline NT‐proBNP.
| Item Type: | Journal Article | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Subjects: | Q Science > QP Physiology R Medicine > RC Internal medicine |
||||||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School | ||||||||||
| SWORD Depositor: | Library Publications Router | ||||||||||
| Library of Congress Subject Headings (LCSH): | Heart failure -- Treatment , Electronics in cardiology, Autonomic nervous system | ||||||||||
| Journal or Publication Title: | European Journal of Heart Failure | ||||||||||
| Publisher: | John Wiley & Sons, Ltd. | ||||||||||
| ISSN: | 1879-0844 | ||||||||||
| Official Date: | September 2022 | ||||||||||
| Dates: |
|
||||||||||
| Volume: | 24 | ||||||||||
| Number: | 9 | ||||||||||
| Page Range: | pp. 1665-1673 | ||||||||||
| DOI: | 10.1002/ejhf.2573 | ||||||||||
| Status: | Peer Reviewed | ||||||||||
| Publication Status: | Published | ||||||||||
| Reuse Statement (publisher, data, author rights): | |||||||||||
| Access rights to Published version: | Open Access (Creative Commons) | ||||||||||
| Copyright Holders: | © 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology | ||||||||||
| Date of first compliant deposit: | 29 July 2022 | ||||||||||
| Date of first compliant Open Access: | 29 July 2022 | ||||||||||
| RIOXX Funder/Project Grant: |
|
||||||||||
| Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
